Seeing Machines starts second study of glaucoma testing device

By Lisa Kerner

Charlotte, N.C., Aug. 30 - Seeing Machines Ltd. said it completed the first phase of its second clinical study (CT2), further exploring the operational parameters of its glaucoma testing device.

A small number of design parameters will be further investigated in an additional clinical study (T13) that began today.

In addition, the company was awarded a Commercial Ready Grant from the Australian Government, allowing for expedited completion of commercialization activities.

Seeing Machines plans to release its glaucoma diagnostic device by the end of the year.

Australian-based Seeing Machines develops advanced computer based imaging software systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.